Skip to main content
S&P 5007,694.89-0.80%DOW52,765.84-0.17%NASDAQ26,313.38-1.46%BTC$81,690.00-2.51%ETH$2,409.54-2.53%GOLD$4,076.90-1.76%OIL$99.10+2.01%
Smart Investors Daily
SID Premium
OS

NYSE · OSTX

OS Therapies Incorporated

Healthcare · Biotechnology

$1.27

Up+$0.01 (+0.79%)

Updated Oct 22, 2026, 1:30 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
71.66M
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
$1.15 – $2.25
Volume
338.05K
Avg. volume
342.06K

Price performance · OSTX

OSTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 21, 2026

OSTX closed at $1.27 after 21 trading sessions, down 23.03% for the selected period.

Last close
$1.27
Period change
-23.03%
Period low
$1.26
Period high
$1.66
Daily close
View OHLC price history
OSTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 21, 2026$1.27$1.33$1.25$1.27338.05K
Oct 20, 2026$1.30$1.34$1.255$1.26320.66K
Oct 19, 2026$1.33$1.3399$1.23$1.27704.74K
Oct 16, 2026$1.42$1.43$1.30$1.32529.17K
Oct 15, 2026$1.38$1.44$1.375$1.41375.24K
Oct 14, 2026$1.45$1.48$1.38$1.39497.35K
Oct 13, 2026$1.57$1.5799$1.45$1.45810.56K
Oct 12, 2026$1.61$1.6234$1.56$1.56247.34K
Oct 9, 2026$1.62$1.66$1.59$1.62422.13K
Oct 8, 2026$1.55$1.68$1.54$1.62664.82K
Oct 7, 2026$1.50$1.5653$1.464$1.55586.74K
Oct 6, 2026$1.71$1.7401$1.47$1.496.02M
Oct 5, 2026$1.61$1.63$1.565$1.60416.2K
Oct 2, 2026$1.625$1.66$1.62$1.62233.39K
Oct 1, 2026$1.62$1.65$1.56$1.61329.64K
Sep 30, 2026$1.60$1.67$1.59$1.60475.09K
Sep 29, 2026$1.64$1.66$1.60$1.61549.52K
Sep 28, 2026$1.66$1.6792$1.61$1.65353.42K
Sep 25, 2026$1.67$1.68$1.64$1.66171.42K
Sep 24, 2026$1.66$1.67$1.615$1.66347.76K
Sep 23, 2026$1.76$1.77$1.64$1.65654.5K

Latest OSTX news

The latest Smart Investors Daily articles mentioning OSTX.

Stock researchCompany · Overview

OSTX research

Overview

Company profile and research snapshot.

Company profile

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.01
Implied upside
—
Analysts
10
OSTX recent ratings
DateFirmRatingTarget
Jul 9, 2026Roth CapitalBuy—
May 19, 2026Lake StreetBuy—
Apr 30, 2026D. Boral CapitalBuy—
Apr 8, 2026D. Boral CapitalBuy—
Mar 27, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Rubenstein Public Relations Named Agency of Record for OS Therapies

Clinical-Stage Oncology Company Taps RPR to Drive Global Communications as Groundbreaking Cancer Immunotherapy Advances Toward ApprovalNEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rubenstein Public Relations (RPR), a leading full-service communications firm, announces it has been named the Agency of Record for OS Therapies, Inc. (NYSE American: OSTX), the world leader in gene-edited, Listeria-based cancer immunotherapies. Recently, OS Therapies announced that it has reached a critical point in ac

Yahoo · Oct 7, 2026

OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma

Received notice for upcoming USDA meetingCompany is reviewing strategic alternatives to monetize OS Animal Health ("OSAH")Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its wholly-owned animal health subsidiary, OSAH received feedback from the U.S. Department of Agriculture (USDA) related to its submission to gain...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By